The peptide guide.
What peptides actually are, how the evidence behind them works, the real difference between research-grade and pharmaceutical-grade, and why "natural" tells you nothing about safety. No hype, no dosing advice. Just sourced information.
Reviewed June 1, 2026
- “Research-grade” is a regulatory label, not a safety grade. Purity ≠ sterility ≠ approved for human use.
- For most research peptides, the honest answer to “does it work in humans?” is not enough data yet, because rodent data regularly fails to translate.
- The approved GLP-1 drugs (semaglutide, tirzepatide) are the only weight-related peptide compounds with large, replicated human RCTs behind them.
- A Certificate of Analysis reports chemistry only. It says nothing about sterility, endotoxins, or long-term safety.
What a peptide actually is.
A peptide is a chain of amino acids: the same building blocks as proteins, just shorter. The dividing line is imprecise, but peptides are generally defined as chains of 2–50 amino acids. The body makes thousands of them naturally as signalling molecules: GLP-1 is a gut peptide, GH-releasing hormone is a hypothalamic peptide, and insulin is technically a small peptide (51 amino acids with a disulfide bridge). The word “peptide” describes a chemistry class, not a pharmacological or safety category.
Structure shapes behaviour. Linear peptides (a single unbranched chain) are the most common in research use. Cyclic peptides, where the chain loops back on itself, are harder to make but far more stable because proteases (enzymes that chew up proteins) can't easily access the backbone. Semaglutide, for example, has an engineered modification at position 8 that blocks the DPP-4 enzyme that destroys natural GLP-1 within minutes, extending its half-life to seven days. Structural engineering is how most approved peptide drugs go from a useful molecule to a usable drug.
The evidence hierarchy, and where most research peptides sit.
Pharmaceutical development has a clear ladder: in-vitro (cell studies) at the bottom, then animal models, then Phase 1 human trials (safety and dose-ranging, typically 20–80 people), Phase 2 (early efficacy signal, hundreds of people), Phase 3 (large randomised controlled trials, thousands of people), and post-market Phase 4 surveillance. Regulatory approval requires at minimum one well-powered Phase 3 trial demonstrating safety and efficacy. The median path from compound discovery to approval takes 10–15 years and costs over a billion dollars.
- 01Animal data doesn't reliably translate. BPC-157 has dozens of rodent studies showing impressive results in gut injury, tendon repair, and wound healing. It has almost no published human trial data. The translation failure rate from animal to human for drugs in general is roughly 90%.
- 02Small trials overstate effect sizes. A 20-person open-label study with no placebo group will almost always show more impressive results than a 2,000-person blinded RCT of the same compound.
- 03Anecdote is not data. Community forum consensus and influencer experience represent placebo-confounded, uncontrolled self-report: exactly the kind of data that has repeatedly failed to predict RCT outcomes.
- 04Approved ≠ effective for your goal. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. That approval does not extend to general body composition use in healthy adults.
How peptides are regulated in the US.
The FDA regulates peptides as drugs when they are intended for human therapeutic use. Getting a peptide approved as a drug requires an Investigational New Drug (IND) application, completion of all trial phases, and a New Drug Application (NDA) with full manufacturing and safety data. The compounds most people discuss fall into four regulatory tiers, which determine what guarantees, if any, exist about quality.
- 01FDA-approved drugs. Human trials completed, NDA approved, manufacturing regulated under GMP (Good Manufacturing Practice). Examples: semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), tesamorelin (EGRIFTA), PT-141/bremelanotide (Vyleesi). Full identity, purity, sterility, and potency controls. Lot-by-lot batch testing. Recall system exists.
- 02Clinical trial phase. IND filed; compound is under investigation. Manufactured under controlled conditions for the trial. Not available commercially. If someone is selling “Phase 3” compounds online, those are not the trial materials.
- 03503A/503B compounding. US compounding pharmacies can prepare certain bulk drug substances for patient-specific use (503A) or larger healthcare settings (503B). Must follow sterility and identity standards, but the compounded product is not FDA-approved. Quality is variable; oversight is inconsistent. Compounded semaglutide and tirzepatide became widespread during supply shortages but carry real identity and purity concerns.
- 04Research-only / grey market. Peptides sold explicitly “not for human use,” but widely self-administered. No regulatory oversight for human use. Certificate of Analysis is the only quality document, and it covers chemistry only. No sterility testing, no endotoxin testing, no validated identity for some exotic sequences.
What a Certificate of Analysis actually tells you.
A Certificate of Analysis (CoA) is the primary quality document for research peptides. It typically shows: identity confirmation (HPLC and often mass spectrometry), purity percentage, and sometimes water content or counterion (TFA vs acetate). This is chemistry testing only.
- 01Sterility. A CoA does not include a sterility test (USP <71>). Bacteria and fungi can be present in a >99% pure sample.
- 02Endotoxins. Endotoxins are fragments of gram-negative bacterial cell walls. They're not caught by HPLC purity testing but can cause fever, septic shock, and organ failure at nanogram-per-kilogram doses. Pharmaceutical manufacturing tests every batch; most research suppliers do not.
- 03Identity for exotic sequences. Some vendors sell peptide analogues or truncations under brand names. Mass spec confirms the molecular weight but may not distinguish an analogue from the actual compound if they have the same mass.
- 04Long-term stability. The CoA reflects the compound when it was tested, not after it has been stored, shipped, or reconstituted.
Common misconceptions: what the evidence actually says.
- 01Myth: “Natural peptide = safe.” Peptides are chains of amino acids. The body makes thousands of them, including toxins. Cone snail venom is peptides. “Natural origin” is biologically meaningless as a safety statement. Efficacy and safety come from the specific sequence, route, dose, and human trial data.
- 02Myth: “If it doesn't work, it's at least harmless.” Research peptides can trigger immunogenicity (antibody formation against the peptide), cause local and systemic reactions, interact with other hormones, and have long-term effects that are completely unstudied at years-long timescales.
- 03Myth: “Stacking compounds is fine, it's additive.” Peptides targeting the GH axis, inflammation pathways, and hormonal systems interact. Stacking without evidence means running unknown interaction profiles with no clinical data and no monitoring framework.
- 04Myth: “The community has figured it out.” Community consensus is the product of survivorship bias (the people harmed often stop posting), placebo response, and uncontrolled self-experimentation. It predicts the outcome of a well-designed RCT no better than a coin flip, historically.
Safety considerations beyond purity.
Even a chemically verified peptide carries safety considerations that don't appear on a CoA. Immunogenicity (the immune system recognising a foreign peptide and mounting an antibody response) reduces efficacy over repeated doses and occasionally causes allergic reactions. The GH secretagogue class (ipamorelin, CJC-1295, sermorelin) drives pituitary GH release; sustained supraphysiological IGF-1 has theoretical carcinogenic and metabolic implications that are not addressed by any long-term human study. For most research peptides, the honest answer to “what are the 5-year effects?” is: we don't know, because nobody has studied it.
- 01Endotoxins (covered above): gram-negative bacterial fragments, fever-inducing at nanogram doses, invisible.
- 02Biofilm on rubber stoppers. Multi-use vials repeatedly punctured can harbour biofilm inside the rubber stopper. Alcohol swabbing kills surface bacteria; it does not penetrate biofilm.
- 03Shaking / mechanical degradation. Vigorous shaking creates air-water interfaces that denature peptide chains and generate aggregates, which can be immunogenic even if the parent peptide was not.
- 04Light exposure. Amino acids with aromatic rings (tryptophan, tyrosine, histidine) absorb UV and visible light. A clear vial under fluorescent lighting can lose 25–40% of tryptophan-containing peptide content within 24 hours.
- 05Temperature abuse. Degradation rate approximately doubles for every 10°C increase. A vial left at room temperature for a day degrades faster than weeks at 4°C.
FAQ.
What's the difference between research-grade and pharmaceutical-grade peptides?
Pharmaceutical-grade means a compound made under regulated GMP manufacturing for human use, with identity, purity, sterility, and endotoxin testing all controlled and an approved label. Research-grade / research-use-only material is sold for laboratory use, is not approved for human administration, and typically only has chemistry testing (HPLC purity) on the CoA. A CoA does not cover sterility, endotoxins, or long-term stability.
How do I know if a peptide is working?
For most research peptides there's no validated biomarker to track, so subjective experience is nearly all you have, and that's exactly where placebo and expectation effects are strongest. The evidence-first approach is to define one or two objective measures before starting (a lab value, a performance metric, a photo series), track consistently, and compare against what's actually published for that compound. The tier board shows how strong that published evidence is.
Do peptides cause cancer?
There's no blanket answer. It depends on the specific compound and mechanism. Growth-signalling peptides (GH secretagogues, IGF-1 pathway compounds) carry theoretical concerns about promoting existing tumour growth, which is why a personal or family history of cancer changes the risk picture. Most research peptides simply lack the long-term human data to answer this definitively, which is the honest position: unknown.
Is BPC-157 safe?
BPC-157 has an impressive rodent safety and efficacy record but almost no human clinical trial data. The rodent data shows no identified lethal dose and anti-inflammatory, gut-protective, and wound-healing effects. Whether those effects translate to humans, at what doses, and over what timeframe, is not established. The compound is not FDA-approved and doesn't have 503A compounding designation, so it exists entirely in the research-only tier. 'No identified toxicity in rodents' is a starting point, not a safety clearance for human use.
Can I stack peptides with TRT or GLP-1?
Many people run peptides alongside TRT/HRT or GLP-1 drugs. Interactions, additive hormonal effects, and monitoring needs are real and individual. Whether a combination is appropriate, and how to monitor it, is a question for a qualified prescriber who knows your history, not a generic guide.
How long can I keep a reconstituted vial?
It depends on the peptide, diluent (bacteriostatic water has a preservative; sterile water doesn't), temperature, handling, and light exposure. There's no single number. As a rough benchmark, bacteriostatic water at refrigerator temperature extends usable life substantially versus sterile water; the reconstitution guide covers the stability factors in detail.
What is lyophilisation?
Lyophilisation is freeze-drying: the peptide is dissolved in water, frozen, then placed in a vacuum chamber where the ice sublimates directly into vapour. The result is a dry powder (often called a 'cake') that is roughly 100× more stable than the same peptide in solution. That's why most research peptides ship as white powder. It's a stability choice, not a mystery.
Why does the tier list show most peptides low on the scale?
Because the tier system grades on human trial evidence. An animal study, no matter how compelling, doesn't move a compound to a high tier. It shows potential and a reason to do human trials, not a basis for claiming clinical efficacy. Most marketed research peptides haven't completed or even initiated well-powered human RCTs, so they sit at the bottom tiers by design. That's an honest reflection of what's published, not a condemnation of the compounds.
Sources.
- [1]Lau JL & Dunn MK: Therapeutic peptides: Historical perspectives, current development trends, and future directions · Bioorg Med Chem, 2018
- [2]Wessman P et al.: Peptide drugs: overview of pharmaceutical approval · Biomed Pharmacother, 2022
- [3]Bray BL: Large-scale manufacture of peptide therapeutics by chemical synthesis · Nat Rev Drug Discov, 2003
- [4]Zapadka KL et al.: Factors affecting the physical stability (aggregation) of peptide therapeutics · Interface Focus, 2017 (PMC5665799)
- [5]FDA: Bulk drug substances used in compounding under Section 503A · U.S. FDA guidance
- [6]USP General Chapter <797>: Pharmaceutical Compounding: Sterile Preparations · United States Pharmacopeia (2023 revision)
- [7]EGRIFTA (tesamorelin): FDA prescribing information · U.S. FDA / DailyMed
- [8]Wegovy (semaglutide): FDA prescribing information · U.S. FDA / DailyMed
- [9]BPC-157: peer-reviewed literature search · PubMed / NCBI
- [10]Nugrahadi PP et al.: Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions · Pharmaceutics, 2023 (PMC10056213)
Cite this page
PepCue. “The peptide guide.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/guides/peptides.
Track your protocol in PepCue.
Log doses, run the calculators, follow the evidence, and keep peptides, GLP-1s, TRT and labs in one private timeline.